Structured evidence table for Calcium Bone Turnover Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Calcium Bone Turnover Randomized Trial | The therapeutic diet emphasized a lower phosphorus-to-protein ratio, higher plant-based content, and increased fiber. | 2 | Peng YS (2026) | Short-term effects of therapeutic diet on bone turnover markers in hemodialysis patients: an exploratory analysis of a randomized crossover trial. |
| Calcium Bone Turnover Randomized Trial | The therapeutic diet significantly increased BAP levels after 7 days (median difference: + 0.8 μg/L, P = 0.02), but did not alter other markers. | 2 | Peng YS (2026) | Short-term effects of therapeutic diet on bone turnover markers in hemodialysis patients: an exploratory analysis of a randomized crossover trial. |
| Calcium Bone Turnover Randomized Trial | Bone turnover abnormalities are common in patients undergoing hemodialysis and contribute to fracture, vascular calcification, and mortality. | 2 | Peng YS (2026) | Short-term effects of therapeutic diet on bone turnover markers in hemodialysis patients: an exploratory analysis of a randomized crossover trial. |
| Calcium Bone Turnover Randomized Trial | Although therapeutic diets targeting phosphate balance improve mineral metabolism, their short-term effects on bone turnover remain unclear. | 2 | Peng YS (2026) | Short-term effects of therapeutic diet on bone turnover markers in hemodialysis patients: an exploratory analysis of a randomized crossover trial. |
| Calcium Bone Turnover Randomized Trial | Accordingly, contemporary guidelines no longer recommend IN-CAL as first-line treatment for chronic osteoporosis, and concerns regarding a potential malignancy signal further limited long-term use. | 3 | Ahmad Areeb (2026) | Revisiting Intranasal Salmon Calcitonin: Historical Osteoporosis Evidence and a Potential Role in Acute Orthopaedic Pain Management |
| Calcium Bone Turnover Randomized Trial | 18 A landmark review by Plosker and McTavish summarized the pharmacologic and clinical evidence for IN-CAL through the mid-1990s. | 3 | Ahmad Areeb (2026) | Revisiting Intranasal Salmon Calcitonin: Historical Osteoporosis Evidence and a Potential Role in Acute Orthopaedic Pain Management |
| Calcium Bone Turnover Randomized Trial | The present review builds upon this foundation by contextualizing historical data and synthesizing subsequent evidence across 3 domains: (1) pharmacology and mechanisms; (2) established and preventive osteoporosis; and (3) acute orthopaedic applications, with particular emphasis on analgesia and time-dependent therapeutic effects. | 3 | Ahmad Areeb (2026) | Revisiting Intranasal Salmon Calcitonin: Historical Osteoporosis Evidence and a Potential Role in Acute Orthopaedic Pain Management |
| Calcium Bone Turnover Randomized Trial | 1 3 - 4 5 , Intranasal salmon calcitonin (IN-CAL) is a peptide antiresorptive agent historically used in the management of postmenopausal osteoporosis, where early randomized trials demonstrated lumbar spine-specific increases in bone mineral density (BMD) with minimal peripheral effects. | 3 | Ahmad Areeb (2026) | Revisiting Intranasal Salmon Calcitonin: Historical Osteoporosis Evidence and a Potential Role in Acute Orthopaedic Pain Management |
Source documents